This is a working overview of circadian clock, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-19 and is reviewed periodically as new material appears.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
== See also == Politics in the United Kingdom 2020s in United Kingdom political history 2023 in United Kingdom politics and government Timeline of the COVID-19 pandemic in the United Kingdom (2023) 2023 in British music 2023 in British television 2023 in British radio List of British films of 2023
Geologists consider her to be the "first woman geologist in this country (America)". 1893: American botanist Elizabeth Gertrude Britton became a charter member of the Botanical Society of America. 1894: American astronomer Margaretta Palmer became the first woman to earn a doctorate in astronomy. 1895: English physiologist Marion Bidder became the first woman to speak and present her own paper at a meeting of the Royal Society. 1896: Florence Bascom became the first woman to work for the United States Geological Survey. 1896: English mycologist and lichenologist Annie Lorrain Smith became a founding member of the British Mycological Society. She later served as president twice. 1896: Russian ophthalmologist Rosa Kerschbaumer-Putjata graduated from the University of Bern. She became the first female doctor permitted to practice in Austria due to a special permit granted by Emperor Franz Joseph I of Austria. She campaigned for women's right to study medicine in Austria. 1897: American cytologists and zoologists Katharine Foot and Ella Church Strobell started working as research partners. Together, they pioneered the practice of photographing microscopic research samples and invented a new technique for creating thin material samples in colder temperatures. 1897: American physicist Isabelle Stone became the first woman to receive a PhD in physics in the United States. She wrote her dissertation "On the Electrical Resistance of Thin Films" at the University of Chicago.
14 August – The annual Government Expenditure and Revenue Scotland report shows a public spending deficit of £22.7bn for Scotland during 2023, an increase of £3.6bn from the previous year. The Scottish Government confirms it will follow the UK government by scrapping universal winter fuel payments for pensioners, with the benefit to be means tested. Staff working on Edinburgh's tram network vote to take strike action over a lack of toilet breaks. 15 August – A shipwreck, believed to be that of HMS Hawke, which was sunk by a torpedo during World War I, has been found off the Aberdeenshire coast. 16 August – 2024 Scottish Conservatives leadership election: Four of the six candidates running for the position of Scottish Conservative leader call for the race to be paused after claims about Douglas Ross's behaviour as leader. The claims concern a report that in July 2023 Ross had asked for the leader of Moray council, Kathleen Robertson, to stand down as the prospective parliamentary candidate for Moray West, Nairn and Strathspey. Meghan Gallacher resigns as the party's deputy leader, citing a "potential risk to the reputation of our party and the leadership contest" after reports that Ross had previously suggested Russell Findlay should succeed him. Developers working on HM Prison Highland in Inverness have uncovered a prehistoric settlement believed to be around 2,000 years old.
Sources: en.wikipedia.org
== Post-1918 House of Hohenzollern == The German Revolution of 1918–1919 dissolved both the constituent German monarchies and the federal compact that created the office of German Emperor. Under Article 109 of the 1919 Weimar Constitution, the legal privileges of the nobility were abolished, ending the constitutional basis for individual monarchical titles and eliminating the legal basis for the imperial federal office. For their part, in late 1918, both Wilhelm II and his heir formally renounced all succession rights. In his formal deed of abdication signed at Amerongen on 28 November 1918, Wilhelm II declared that he renounced "for all time claims to the throne of Prussia and to the German Imperial throne connected therewith." Crown Prince Wilhelm similarly executed a deed of renunciation on 1 December 1918, forfeiting his succession rights to both the Prussian and imperial crowns. After 1918, the House of Hohenzollern continued to use its traditional dynastic house laws primarily to govern the succession of family trusts and private estate inheritance. In 2004, the Federal Constitutional Court of Germany confirmed that these historical house laws possess no public-law standing and operate strictly within the framework of private civil law, with headship of the family functioning as a private lineage rather than a constitutional office.
Cysteine dioxygenase (CDO), and sulfinoalanine decarboxylase can turn cysteine into hypotaurine and then taurine. Alternately, the cysteine from the cystathionine gamma-lyase can be used by the enzymes glutamate–cysteine ligase (GCL) and glutathione synthetase (GSS) to produce glutathione.
At 7:59 a.m., American Airlines Flight 11 took off from Logan International Airport in Boston. About fifteen minutes into the flight, five hijackers armed with boxcutters took over the plane, injuring at least three people and possibly killing one, before forcing their way into the cockpit. The terrorists also displayed an apparent explosive and sprayed mace into the cabin, to frighten the hostages into submission and further hinder resistance. Back at Logan, United Airlines Flight 175 took off at 8:14 a.m. Hundreds of miles southwest at Dulles International Airport, American Airlines Flight 77 left the runway at 8:20 a.m. Flight 175's journey proceeded normally for 28 minutes until 8:42 am, when a group of five hijacked the plane, murdering both pilots and stabbing several crew members before assuming control of the aircraft. These hijackers also used bomb threats to instill fear into the passengers and crew, also spraying "tear gas, pepper spray or another irritant" in the cabin to force passengers and flight attendants to the rear of the cabin. Concurrently, United Airlines Flight 93 departed from Newark International Airport in New Jersey; originally scheduled to pull away from the gate at 8:00 a.m., the plane was running 42 minutes late. At 8:46 a.m., Flight 11 was deliberately crashed into the north face of the World Trade Center's North Tower between the 93rd and 99th floors. The initial presumption by many was that it was an accident.
Sources: en.wikipedia.org
Sikhism is a monotheistic tradition founded by Guru Nanak in the late 15th-century Punjab; it grew into a tight-knit fellowship under later gurus, the last guru ceding authority to the holy book Guru Granth Sahib. Buddhism, founded by the Buddha in the mid-5th century BCE in the middle Ganges plain, eventually spread beyond India to Southeast Asia and East Asia, even as it waned in its homeland; nevertheless, its statues and stupas—stone realisations of the Buddha—remain prominent across the subcontinent, drawing pilgrims from around the world. Jainism, anciently contemporaneous with Buddhism, has two main sects, Śvetāmbara, whose monks and nuns wear robes and use bowls to receive alms, and Digambara, whose monks go naked and cup their hands for alms. Jains today, regardless of sect, have aligned themselves with environmentalism. The Parsis follow Zoroastrianism; they arrived on India's western coast from Iran late in the first millennium CE and rose in trade and industry, becoming early leaders of Indian nationalism. The Qissa-i Sanjan records their legendary arrival and welcome in India. Judaism, which had become established in India by the 8th-century CE, was never subject to antisemitism from Hindus, Christians, or Parsis, nor to ethnic tensions from Indian Muslims; it has preserved distinctive Indo-Judaic customs. India has had a long history of religious pluralism that shapes its modern society. A large majority of Indian Muslims, Christians, and Sikhs participate in customs, or adhere to beliefs, that were once unique to Hinduism (e.g. karma).
Later in September Roche announced its intention to acquire Tusk Therapeutics for up to €655 million ($759 million) expanding Roche's oncology pipeline. Tusk announced that the anti-CD38 antibody it is developing will be spun off to form a new company, Black Belt Therapeutics. In late November, the company announced that Genentech would acquire Jecure Therapeutics, gaining access to Jecure's portfolio of NLRP3 inhibitors developed to fight inflammatory diseases like non-alcoholic steatohepatitis and liver fibrosis. In February 2019, the business announced it would acquire gene therapy company, Spark Therapeutics, for US$4.3 billion ($114.50 per share) adding Spark's gene therapy portfolio to its previous acquired assets. Spark has an already approved treatment for Leber's congenital amaurosis, Luxturna – priced at US$850,000 per patient. The offer to acquire Spark Therapeutics was extended to May 2019 after Roche was unable to garner majority support from Spark shareholders. A second gene therapy-related action came in December with the US$1.15 billion acquisition of non-United States rights to an investigational duchenne muscular dystrophy gene therapy developed by Sarepta Therapeutics. In November, Roche acquired Promedior and its lead treatment – PRM-151 – for the treatment of idiopathic pulmonary fibrosis, for $390 million upfront and another $1 billion in milestone payments.
==== Differential mobility spectrometry (DMS) ==== Also known as field asymmetric-waveform ion mobility spectrometry (FAIMS) or RF-DC ion mobility spectrometry is a technique in which ions are separated by the application of a high-voltage asymmetric waveform at radio frequency (RF) combined with a static (DC) waveform applied between two electrodes. Depending on the ratio of the high-field and low-field mobility of the ion, it will migrate toward one or the other electrode. Only ions with specific mobility will pass through the device. It is well known that the high RF field distort the conformation of the ions, FAIMS thus is a separation technique without preserving the structure of the ions and the CCSs of the ions cannot be measured. Because FAIMS is a mass selector (other ions are excluded), the sensitivity in the scan mode is much lower than that of the drift tube ion mobility (all the ions are analyzed). Therefore, FAIMS is usually coupled with triple quadrupole mass spectrometer which is also ion selection type instrument.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.